Synergistic antitumor efficacy of oncolytic adenovirus combined with chemotherapy

Chinese Journal of Cancer Research

Volumn 19, Issue 2, 2007, Pages 76-81

  Li, Yue Min ^a   Song, San Tai ^a   Jiang, Ze Fei ^a   Zhang, Qi ^b   Qu, Yi Mei ^c   Su, Chang Qing ^b   Zhao, Chuan Hua ^a   Li, Zhi Qiang ^a   Ge, Fei Jiao ^d   Qian, Qi Jun ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d NONE

Author keywords

CNHK300; hTERT; Oncolytic adenovirus; Virotherapy

Indexed keywords

ONCOLYTIC ADENOVIRUS; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

EID: 34347226257     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-007-0076-7     Document Type: Article

References (24)

1. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers[J]. Cancer Res 2000; 60: 5359-64.
2. Majumdar AS, Hughes DE, Lichtsteiner SP, et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters[J]. Gene Ther 2001; 8: 568-78.
3. Koga S, Hirohata S, Kondo Y, et al. a novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter[J]. Hum Gene Ther 2000; 11: 1397-406.
4. Tsukuda K, Wiewrodt R, Molnar-kimber K, et al. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell[J]. Cancer Res 2002; 62: 3438-47.
5. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen[J]. J Clin Invest 2000; 106: 763-71.
6. Su CQ, Xue HB, Wang XH, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting to the telomerase-positive cancer cells[J]. J Cancer Res Clin Oncol 2004; 130: 591-603.
7. Li YM, Song ST, Jiang ZF, et al. hTERT promoter regulated replication-selective adenovirus CNHK300 in the treatment of heptocellular carcinoma[J]. Zhonghua Yixue Zazhi 2005; 85: 468-72.
8. Carlos Caldas, Samuel AJ, Aparicio. The molecular outlook[J]. Nature 2002; 415: 484-5.
9. Press MF, Pike MG, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease[J]. Cancer Res 1993; 53: 4960-70.
10. Bianchi S, Palli D, Falchetti M, et al. ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study[J]. J Cell Physiol 2006; 206:702-8.
11. Chou TC, Talalay, P. Quantitative analysis of dose-effect relationship: the combined effect of multiple drugs or enzyme inhibitors[J]. Adv Enzyme Regul 1984; 22: 27-55.
12. Ramon Alemany, Cristina Balague, David T. Curiel. Replicative adenoviruses for cancer therapy[J]. Nat Biotechnol 2000; 18: 723-7.
13. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science 1996; 274: 373-6.
14. Fisher K. striking out at disseminated metastases: the systemic delivery of oncolytic viruses[J]. Curr Opin Mol Ther 2006; 8: 301-13.
15. Irving J, Wang Z, Powell S, et al. conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity[J]. Cancer Gene Ther 2004; 11: 174-85.
16. Huang TG, Savontaus MJ, Shinozaki K, et al. Telomerase-dependent oncolytic adenovirus for cancer treatment[J]. Gene Ther 2003; 10: 1241-7.
17. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer[J]. Cancer Res 2003; 63: 3181-8.
18. Khuri F, Nemunaitis J, Ganly I. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med 2000; 6: 879-85.
19. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines an primary cultures freshly made from lung cancer patients[J]. Cancer Res 2000; 60: 1009-13.
20. Nemunaitis J, Cunningham G, Tong AW, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients[J]. Cancer Gene Ther 2003; 10: 341-52.
21. Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy inpatients with advanced sarcomas[J]. Gene Ther 2005; 12: 437-45.
22. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel[J]. Cancer Res 2001; 61: 517-25.
23. Chen Y, DeWeese T, Zhang Y, et al CV706, a prostate cancer-specific adenovirus variant, in comnbination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity[J]. Cancer Res 2001; 61: 5453-60.
24. Nguyen KH, Hachem P, Khor LY, et al. Adenoviral-E2F-1 radiosensitizes p53 wild-type and p53 null human prostate cancedr cells[J]. Int J Radiat Oncol Biol Phys 2005; 63: 238-46.